Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 113Breast Neoplasms 80Neoplasms 75Neoplasm Metastasis 63Colorectal Neoplasms 63Prostatic Neoplasms 59Recurrence 57Leukemia, Myeloid, Acute 55Pancreatic Neoplasms 54Ovarian Neoplasms 53Multiple Myeloma 52Melanoma 40Glioblastoma 40Squamous Cell Carcinoma of Head and Neck 33Lung Neoplasms 33Triple Negative Breast Neoplasms 31Lymphoma, Non-Hodgkin 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Endometrial Neoplasms 30Carcinoma, Renal Cell 28Lymphoma 27Lymphoma, Large B-Cell, Diffuse 26Carcinoma, Hepatocellular 26Stomach Neoplasms 25Lymphoma, B-Cell 25Small Cell Lung Carcinoma 24Leukemia, Lymphocytic, Chronic, B-Cell 24Brain Neoplasms 24Advanced Solid Tumor 24Myelodysplastic Syndromes 23

Interventions

selinexor 1pazopanib 1Proton Therapy 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Granuloma, Plasma Cell × 90 days × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡